Comparative genomic hybridisation (CGH) allows to detect genetic abnormalities associated with poor prognosis in subset of patients with diffuse large B-cell lymphoma (DLBCL). Amplification of 2p13-16 represents an adverse genetic sign especially in extranodal DLBCL. In the present case, 2p13-16 amplification was revealed by CGH in extranodal DLBCL. It was localized in the mesentery and remained resistant to the chemotherapy (CHOP). A patient, 72-year-old female, died 10 weeks after the diagnosis had been made. Rapid lethal course of the disease confirms poor outlook for patients with 2p13-16 and supports a role of CGH as a sensitive method in prognosis for patients with DLBCL.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!